Health: A Drug That Starves Tumors

When the FDA approved Genentech's colorectal cancer drug Avastin last week, it also validated a cancer-fighting strategy proposed more than 30 years ago. Avastin is the first in what researchers hope will be a whole new class of drugs called angiogenesis inhibitors, which attack tumors by thwarting their ability to create blood vessels--thus starving cancer cells of oxygen and nutrients. In trials, Avastin has been shown to give patients, on average, an additional five months of life. Cost of a 10month course of treatment: about $50,000. --D.B.

...

Want the full story?

Subscribe Now

Subscribe
Subscribe

Get TIME the way you want it

  • One Week Digital Pass — $4.99
  • Monthly Pay-As-You-Go DIGITAL ACCESS$2.99
  • One Year ALL ACCESSJust $30!   Best Deal!
    Print Magazine + Digital Edition + Subscriber-only Content on TIME.com

Learn more about the benefits of being a TIME subscriber

If you are already a subscriber sign up — registration is free!